DBV Technologies S.A.
NASDAQ:DBVTBiotechnology
-$0.16 today
- Market cap
- $238.98M
- Beta
- -0.22
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.39
Volume 0.17M
Average 0.24M
DBVT Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
DBV Technologies S.A.NASDAQ: DBVT
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit remains negative
Q1 FY2026 gross profit was -$4.22M, compared with -$4.48M a year earlier. Trailing-twelve-month gross profit was -$17.4M.
Context
- Gross profit increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near -$4.22M or moves back toward the trailing-twelve-month quarterly average of -$4.35M.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- (17.67M) USD
- Year-over-year change
- -159.4%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (17.67M) | -159.4% |
| FY2024 | 2024-12-31 | (6.81M) | -143.3% |
| FY2023 | 2023-12-31 | 15.73M | +201.5% |
| FY2022 | 2022-12-31 | (15.5M) | -334.8% |
| FY2021 | 2021-12-31 | (3.57M) | — |
Gross Profit vs competitors
How DBVT compares with its peers on the latest reported figures
- DBVT's LTM Mar 2026 gross profit of -$17.4M is the lowest of the 11 companies compared; the peer median is -$183K.
- Its year-over-year change of -146.9% is the 5th highest of 6, against a peer median of -41.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $112.77M | +52.6% | -20.7% | 52.5% | |
| LTM Mar 2026 | $55.76M | +43.8% | +80.8% | 81.9% | |
| LTM Mar 2026 | $2.81M | -41.7% | — | 73.2% | |
| LTM Mar 2026 | $0 | — | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | -$82K | — | — | — |
| LTM Mar 2026 | -$284K | -67.1% | — | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | -$369K | — | — | — |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$546K | — | — | — |
| LTM Mar 2026 | -$1.9M | — | — | — | |
| LTM Mar 2026 | -$14.95M | -74835.0% | — | 41519.4% | |
| LTM Mar 2026 | -$17.4M | -146.9% | — | — | |
| Peer median (excluding DBVT) | -$183K | -41.7% | +30.0% | 77.6% | |
Competitors are the stored peer set for DBVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.71M | 4.8M | 15.73M | 0 | 0 |
| Cost of Revenue | 9.27M | 20.3M | 0 | 6.81M | 17.67M |
| Gross Profit | (3.57M) | (15.5M) | 15.73M | (6.81M) | (17.67M) |
| Gross Margin | -62.5% | -322.9% | 100.0% | — | — |
| Research & Development | 70.34M | 75.5M | 60.22M | 89.9M | 116.68M |
| Selling, General & Admin | 23.83M | 17.56M | 31.94M | 23.81M | 28.28M |
| Operating Expenses | 93.93M | 101.48M | 92.16M | 113.71M | 147.06M |
| Depreciation & Amortization | 8.38M | 20.3M | 13.16M | 6.81M | 7.73M |
| EBITDA | (91.16M) | (76.68M) | (63.27M) | (110.99M) | (139.32M) |
| EBITDA Margin | -1597.0% | -1597.5% | -402.3% | — | — |
| Operating Income | (98.61M) | (96.63M) | (76.43M) | (120.53M) | (147.06M) |
| Operating Margin | -1727.6% | -2013.1% | -486.0% | — | — |
| Interest Income | 521K | 406.29K | 3.71M | 2.73M | 601.86K |
| Interest Expense | 690K | 427K | 0 | 0 | 0 |
| Other Income / Expenses | 424K | 427K | 3.71M | 2.73M | 600K |
| Income Before Tax | (98.19M) | (96.2M) | (72.72M) | (117.8M) | (146.46M) |
| Pre-Tax Margin | -1720.2% | -2004.3% | -462.4% | — | — |
| Income Tax Expense | (381K) | 70K | 7K | (4.08M) | 491K |
| Net Income | (97.81M) | (96.3M) | (72.73M) | (113.72M) | (146.95M) |
| Net Margin | -1713.5% | -2006.3% | -462.4% | — | — |
| EPS (Basic) | (1.80) | (1.25) | (0.75) | (1.20) | (1.70) |
| EPS (Diluted) | (1.80) | (1.25) | (0.75) | (1.20) | (1.70) |
| Weighted Avg Shares | 55.1M | 77.38M | 95.12M | 96.17M | 86.4M |
| Weighted Avg Shares (Diluted) | 55.1M | 77.38M | 95.12M | 96.17M | 86.4M |
DBV Technologies S.A.
NASDAQ:DBVT
Intrinsic Alpha fair value
Locked
Current Price
$9.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.